What is Spear Bio?
Spear Bio, established in 2021 by former Harvard researchers Feng Xuan and Peng Yin, is a Woburn, MA-based biotechnology firm. The company is dedicated to advancing ultrasensitive immunoassay technology. Spear Bio collaborates with academic researchers, clinicians, and industry partners to pioneer more sensitive detection methods and versatile assay approaches. These innovations aim to support non-invasive sample collection and enhance cutting-edge laboratory diagnostics.
How much funding has Spear Bio raised?
Spear Bio has raised a total of $49M across 2 funding rounds:
Angel/Seed
$4M
Series A
$45M
Angel/Seed (2021): $4M, investors not publicly disclosed
Series A (2024): $45M led by Bio-Techne and Foresite Capital
Key Investors in Spear Bio
Bio-Techne
Bio-Techne Corporation, founded in 1981, is a global life sciences company providing innovative tools and bioactive reagents for research and clinical diagnostics. They support scientific investigations into biological processes and disease, aiding drug discovery and enabling accurate clinical tests.
Foresite Capital
Foresite Capital is a multi-stage investment firm focused on transforming healthcare and life sciences through investments in companies leveraging biology and big data. They employ a data science-driven approach to address unmet needs in healthcare by funding visionary businesses.
What's next for Spear Bio?
The recent major enterprise-level funding, characterized as a strategic investment, positions Spear Bio for significant scaling and further development of its proprietary immunoassay technology. This capital infusion is expected to accelerate the company's go-to-market strategy, expand its research and development capabilities, and solidify its collaborations within the diagnostics and life sciences sectors. Spear Bio's focus on non-invasive sample collection and advanced laboratory diagnostics aligns with growing market demands for more efficient and accurate healthcare solutions.
See full Spear Bio company page
